Short answer
Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on June 30, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). VOICE trial interim analysis met predefined stopping criteria.
Akebia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- VOICE trial interim analysis met predefined stopping criteria
- Vafseo demonstrated non-inferiority and superiority on the primary composite endpoint
- USRC Kidney Research decided to stop the trial based on interim results
- Press release furnished as Exhibit 99.1; outcome potentially supports Vafseo’s clinical and commercial positioning
Item 8.01 · Other Events
- VOICE trial stopped early after 2,116 patients met prespecified non-inferiority and superiority criteria for Vafseo versus standard ESA
- Vafseo achieved win odds 1.16, 95% CI 1.06–1.28, p=0.0016, strengthening its dialysis anemia treatment profile
- Hospitalizations declined to 1.11 versus 1.23 per patient-year, incidence rate ratio 0.90
- Mortality was statistically comparable: 8.77% versus 8.78% per 100 patient-years
- Positive interim results could support Vafseo adoption and improve Akebia’s competitive positioning in dialysis care
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Akebia Therapeutics, Inc. 8-K filings
Get the next AKBA 8-K as it lands
Follow AKBA for push alerts, or ask the research agent what this filing means.